Ultragenyx Pharmaceutical (RARE) Short Interest Ratio & Short Volume $31.69 -0.33 (-1.03%) Closing price 10/14/2025 04:00 PM EasternExtended Trading$32.36 +0.67 (+2.11%) As of 10/14/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Ultragenyx Pharmaceutical Short Interest DataUltragenyx Pharmaceutical (RARE) has a short interest of 7.95 million shares. This marks a -4.45% decrease in short interest from the previous month. The short interest ratio (days to cover) is 3.9, indicating that it would take 3.9 days of the average trading volume of 1.73 million shares to cover all short positions.Current Short Interest7,950,000 sharesPrevious Short Interest8,320,000 sharesChange Vs. Previous Month-4.45%Dollar Volume Sold Short$230.55 millionShort Interest Ratio3.9 Days to CoverLast Record DateSeptember 15, 2025Outstanding Shares96,370,000 sharesPercentage of Shares Shorted8.25%Today's Trading Volume1,229,102 sharesAverage Trading Volume1,729,951 sharesToday's Volume Vs. Average71% Short Selling Ultragenyx Pharmaceutical? Sign up to receive the latest short interest report for Ultragenyx Pharmaceutical and its competitors with MarketBeat's FREE newsletter. Email Address Get Report View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartRARE Short Interest Over TimeRARE Days to Cover Over TimeRARE Percentage of Float Shorted Over Time Ultragenyx Pharmaceutical Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 9/15/20257,950,000 shares $230.55 million -4.5%N/A3.9 $29.00 8/31/20258,320,000 shares $249.27 million -1.1%9.1%4.3 $29.96 8/15/20258,410,000 shares $249.69 million +10.1%N/A4.4 $29.69 7/31/20257,640,000 shares $208.72 million -13.2%8.4%4.2 $27.32 7/15/20258,800,000 shares $239.36 million +29.0%N/A5.3 $27.20 6/30/20256,820,000 shares $247.98 million +12.2%7.6%5.3 $36.36 6/15/20256,080,000 shares $227.94 million +9.6%6.8%6 $37.49 5/31/20255,550,000 shares $187.98 million -5.8%6.4%5.9 $33.87 5/15/20255,890,000 shares $205.21 million +6.3%6.8%6.6 $34.84 4/30/20255,540,000 shares $215.95 million +1.5%N/A6.3 $38.98 Get the Latest News and Ratings for RARE and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Ultragenyx Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. 4/15/20255,460,000 shares $192.96 million +20.5%6.3%6.6 $35.34 3/31/20254,530,000 shares $164.03 million -5.8%5.2%5.4 $36.21 3/15/20254,810,000 shares $189.23 million +4.8%5.5%5.7 $39.34 2/28/20254,590,000 shares $197.00 million +7.2%5.3%5.4 $42.92 2/15/20254,280,000 shares $181.86 million +2.9%4.9%5.4 $42.49 1/31/20254,160,000 shares $179.00 million -2.1%N/A5 $43.03 1/15/20254,250,000 shares $174.17 million +5.7%N/A4.8 $40.98 12/31/20244,020,000 shares $169.12 million +8.4%N/A5 $42.07 12/15/20243,710,000 shares $169.84 million +9.8%N/A5 $45.78 11/30/20243,380,000 shares $160.99 million +0.9%N/A4.8 $47.63 11/15/20243,350,000 shares $149.91 million +5.4%N/A4.7 $44.75 10/31/20243,180,000 shares $162.15 million +0.6%N/A4.5 $50.99 10/15/20243,160,000 shares $180.50 million +9.3%N/A4.7 $57.12 9/30/20242,890,000 shares $160.54 million -19.9%N/A4.1 $55.55 9/15/20243,610,000 shares $212.05 million +2.9%N/A4.7 $58.74 8/31/20243,510,000 shares $199.30 million -8.8%N/A4.1 $56.78 8/15/20243,850,000 shares $199.16 million -9.0%N/A4.3 $51.73 7/31/20244,230,000 shares $190.43 million -3.0%N/A4.8 $45.02 7/15/20244,360,000 shares $193.85 million +2.8%N/A5.1 $44.46 6/30/20244,240,000 shares $174.26 million -15.9%N/A4.8 $41.10 6/15/20245,040,000 shares $196.81 million +12.8%N/A6.2 $39.05 5/31/20244,470,000 shares $179.43 million +3.0%N/A6.1 $40.14 5/15/20244,340,000 shares $178.46 million -6.7%N/A5.9 $41.12 4/30/20244,650,000 shares $197.81 million +6.2%N/A6.3 $42.54 4/15/20244,380,000 shares $187.77 million +11.7%N/A6.3 $42.87 3/31/20243,920,000 shares $183.02 million +3.7%N/A5.3 $46.69 3/15/20243,780,000 shares $179.06 million -2.3%N/A5 $47.37 2/29/20243,870,000 shares $200.16 million +8.7%N/A4.9 $51.72 2/15/20243,560,000 shares $164.69 million +4.4%N/A4.6 $46.26 1/31/20243,410,000 shares $150.42 million -17.2%N/A4.3 $44.11 1/15/20244,120,000 shares $188.28 million +1.5%N/A4.4 $45.70 12/31/20234,060,000 shares $194.15 million +21.6%N/A4.1 $47.82 12/15/20233,340,000 shares $153.54 million +3.1%N/A3.4 $45.97 11/30/20233,240,000 shares $125.87 million -7.4%N/A3.4 $38.85 11/15/20233,500,000 shares $136.78 million -15.9%N/A3.8 $39.08 10/31/20234,160,000 shares $147.26 million +24.6%N/A4.6 $35.40 10/15/20233,340,000 shares $112.12 million -15.0%5.0%4 $33.57 9/30/20233,930,000 shares $140.10 million +15.6%5.9%6.3 $35.65 9/15/20233,400,000 shares $128.11 million -1.5%5.1%6 $37.68 8/31/20233,450,000 shares $126.93 million -1.7%5.2%6.2 $36.79 8/15/20233,510,000 shares $134.75 million -1.1%5.3%6.2 $38.39 7/31/20233,550,000 shares $153.08 million -10.4%5.4%5.9 $43.12 7/15/20233,960,000 shares $174.95 million +6.5%6.0%6.4 $44.18 6/30/20233,720,000 shares $171.60 million +22.0%5.7%5.7 $46.13 6/15/20233,050,000 shares $149.02 million -4.1%4.7%4.5 $48.86 5/31/20233,180,000 shares $156.96 million -8.9%4.9%4.8 $49.36 5/15/20233,490,000 shares $171.08 million +17.1%5.3%5.5 $49.02 4/30/20232,980,000 shares $130.14 million +4.2%4.6%4.9 $43.67 4/15/20232,860,000 shares $109.25 million -8.0%4.4%4.8 $38.20 3/31/20233,110,000 shares $124.71 million +4.4%4.8%5.2 $40.10 3/15/20232,980,000 shares $121.38 million -3.3%4.6%5 $40.73 2/28/20233,080,000 shares $137.03 million -6.4%4.7%4.8 $44.49 2/15/20233,290,000 shares $145.45 million -3.2%5.1%4.8 $44.21 1/31/20233,400,000 shares $154.12 million -4.8%5.2%4.6 $45.33 1/15/20233,570,000 shares $155.47 million +6.3%5.5%4.7 $43.55 12/30/20223,360,000 shares $155.67 million -1.2%5.2%4.3 $46.33 12/15/20223,400,000 shares $154.94 million +14.1%5.2%4.2 $45.57 11/30/20222,980,000 shares $108.17 million -1.3%4.6%3.8 $36.30 11/15/20223,020,000 shares $107.09 million +2.0%4.7%4.1 $35.46 10/31/20222,960,000 shares $119.76 million -8.6%4.6%4.1 $40.46 10/15/20223,240,000 shares $120.07 million +5.9%5.0%4.5 $37.06 9/30/20223,060,000 shares $126.71 million -1.9%4.7%4.1 $41.41 9/15/20223,120,000 shares $147.51 million +6.5%4.8%4.5 $47.28 8/31/20222,930,000 shares $139.73 million -3.9%4.5%4.2 $47.69 8/15/20223,050,000 shares $156.16 million +7.4%4.7%4.4 $51.20 7/31/20222,840,000 shares $151.32 million -5.0%4.4%4.1 $53.28 7/15/20222,990,000 shares $193.60 million +3.5%4.6%4.6 $64.75 6/30/20222,890,000 shares $172.42 million +7.0%4.5%5.1 $59.66 6/15/20222,700,000 shares $136.92 million +0.4%4.2%4.9 $50.71 5/31/20222,690,000 shares $126.16 million -10.9%4.2%5.2 $46.90 5/15/20223,020,000 shares $155.44 million -1.3%4.7%6.2 $51.47 4/30/20223,060,000 shares $216.31 million +5.9%4.8%6.9 $70.69 4/15/20222,890,000 shares $246.81 million +2.5%4.5%6.7 $85.40 3/31/20222,820,000 shares $204.79 million -3.8%4.4%6.6 $72.62 3/15/20222,930,000 shares $186.61 million -3.3%4.6%7.1 $63.69 2/28/20223,030,000 shares $203.98 million -8.5%4.7%7.3 $67.32 2/15/20223,310,000 shares $243.45 million -4.9%5.2%7.6 $73.55 1/31/20223,480,000 shares $243.36 million -0.3%5.5%8.5 $69.93 1/15/20223,490,000 shares $251.45 million +0.6%5.5%8.5 $72.05 12/31/20213,470,000 shares $291.79 million -11.5%5.5%8.2 $84.09 12/15/20213,920,000 shares $325.56 million -1.3%6.2%9.2 $83.05 11/30/20213,970,000 shares $298.66 million -2.7%6.3%9.5 $75.23 11/15/20214,080,000 shares $328.60 million +10.3%6.5%10.6 $80.54 10/29/20213,700,000 shares $310.50 million -3.9%5.9%9.1 $83.92 10/15/20213,850,000 shares $308 million -4.0%6.1%9.3 $80.00 9/30/20214,010,000 shares $361.66 million +3.9%6.4%9.7 $90.19 9/15/20213,860,000 shares $374.42 million -4.0%6.1%7 $97.00 8/31/20214,020,000 shares $387.09 million -0.7%6.4%6.7 $96.29 8/13/20214,050,000 shares $375.60 million -0.5%6.4%6.6 $92.74 7/30/20214,070,000 shares $324.91 million +3.0%6.5%6.6 $79.83 7/15/20213,950,000 shares $334.76 million +4.5%6.3%6.5 $84.75 6/30/20213,780,000 shares $360.42 million -23.6%6.0%6.3 $95.35 6/15/20214,950,000 shares $495.20 million -2.6%7.8%10.4 $100.04 5/28/20215,080,000 shares $516.69 million -1.0%8.0%11.6 $101.71 5/14/20215,130,000 shares $547.42 million -6.0%N/A12.1 $106.71 4/30/20215,460,000 shares $619.76 million +1.1%N/A12.4 $113.51 4/15/20215,400,000 shares $583.04 million -2.0%N/A13.1 $107.97 3/31/20215,510,000 shares $617.45 million -0.5%N/A12.1 $112.06 3/15/20215,540,000 shares $703.30 million -5.5%N/A11.2 $126.95 2/26/20215,860,000 shares $798.43 million +10.4%N/A11.6 $136.25 2/12/20215,310,000 shares $864.36 million -0.4%N/A10.9 $162.78 1/29/20215,330,000 shares $749.40 million -3.3%N/A11.3 $140.60 1/15/20215,510,000 shares $770.68 million -5.3%N/A10.1 $139.87 12/31/20205,820,000 shares $840.23 million -7.6%N/A11.3 $144.37 12/15/20206,300,000 shares $965.29 million -4.1%N/A14.2 $153.22 11/30/20206,570,000 shares $804.30 million -4.0%N/A15.4 $122.42 11/15/20206,840,000 shares $801.78 million -3.3%N/A16.4 $117.22 10/30/20207,070,000 shares $671.65 million -4.3%N/A17.4 $95.00 10/15/20207,390,000 shares $684.98 million +5.4%13.2%22.3 $92.69 RARE Short Interest - Frequently Asked Questions What is Ultragenyx Pharmaceutical's current short interest? Short interest is the volume of Ultragenyx Pharmaceutical shares that have been sold short but have not yet been covered or closed out. As of September 15th, traders have sold 7,950,000 shares of RARE short. Learn More on Ultragenyx Pharmaceutical's current short interest. What is a good short interest ratio for Ultragenyx Pharmaceutical? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. RARE shares currently have a short interest ratio of 4.0. Learn More on Ultragenyx Pharmaceutical's short interest ratio. Which institutional investors are shorting Ultragenyx Pharmaceutical? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Ultragenyx Pharmaceutical: Hudson Bay Capital Management LP, Nomura Holdings Inc., Moore Capital Management LP, LMR Partners LLP, Hudson Bay Capital Management LP, Group One Trading LLC, Boothbay Fund Management LLC, Jane Street Group LLC, Caption Management LLC, Diadema Partners LP, Walleye Capital LLC, Walleye Trading LLC, and Persistent Asset Partners Ltd. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Ultragenyx Pharmaceutical's short interest increasing or decreasing? Ultragenyx Pharmaceutical saw a decline in short interest during the month of September. As of September 15th, there was short interest totaling 7,950,000 shares, a decline of 4.4% from the previous total of 8,320,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Ultragenyx Pharmaceutical's short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Ultragenyx Pharmaceutical: Roivant Sciences Ltd. (8.72%), Moderna, Inc. (18.43%), Qiagen N.V. (3.10%), BridgeBio Pharma, Inc. (10.17%), Elanco Animal Health Incorporated (5.51%), Verona Pharma PLC American Depositary Share (2.36%), Revolution Medicines, Inc. (9.66%), Cytokinetics, Incorporated (12.19%), Merus N.V. (5.73%), Avidity Biosciences, Inc. (15.24%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Corporation ($8.81 billion), Canadian Natural Resources Limited ($5.82 billion), Reddit Inc. ($5.19 billion), Coinbase Global, Inc. ($4.52 billion), Robinhood Markets, Inc. ($4.30 billion), Charter Communications, Inc. ($3.75 billion), CoreWeave Inc. ($3.66 billion), Seagate Technology Holdings PLC ($3.57 billion), Live Nation Entertainment, Inc. ($3.33 billion), and Rocket Lab Corporation ($3.26 billion). View all of the most shorted stocks. What does it mean to sell short Ultragenyx Pharmaceutical stock? Short selling RARE is an investing strategy that aims to generate trading profit from Ultragenyx Pharmaceutical as its price is falling. RARE shares are trading down $0.33 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Ultragenyx Pharmaceutical? A short squeeze for Ultragenyx Pharmaceutical occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of RARE, which in turn drives the price of the stock up even further. How often is Ultragenyx Pharmaceutical's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including RARE, twice per month. The most recent reporting period available is September, 15 2025. More Short Interest Resources from MarketBeat Related Companies ROIV Short Interest Data MRNA Short Interest Data QGEN Short Interest Data BBIO Short Interest Data ELAN Short Interest Data VRNA Short Interest Data RVMD Short Interest Data CYTK Short Interest Data MRUS Short Interest Data RNA Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:RARE) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ultragenyx Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ultragenyx Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
